Xenon Pharmaceuticals Inc.
XENE
$37.11
-$0.40-1.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -39.77% | -33.32% | -28.48% | -21.90% | -21.58% |
| Total Depreciation and Amortization | 11.19% | 13.48% | 22.71% | -60.47% | 27.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 47.44% | 98.37% | 87.86% | 181.64% | 54.70% |
| Change in Net Operating Assets | -2,921.09% | 57.05% | -13.18% | -62.88% | -96.38% |
| Cash from Operations | -43.90% | -21.76% | -21.02% | -10.40% | -22.98% |
| Capital Expenditure | 47.21% | 18.59% | 45.26% | 67.49% | 53.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 287.14% | 225.06% | 260.31% | -239.62% | 30.16% |
| Cash from Investing | 281.18% | 221.36% | 249.47% | -250.62% | 31.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.22% | -96.24% | -96.57% | 997.83% | 50,044.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -96.22% | -96.24% | -96.57% | 997.83% | 50,044.96% |
| Foreign Exchange rate Adjustments | 12.44% | -2,638.00% | -544.68% | -128.50% | 58.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -101.87% | 644.09% | -106.49% | -205.31% | 123.63% |